Janagliflozin
Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1) . Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus[1][2].
Product Specifications
CAS Number
1800115-22-3
UNSPSC
12352005
Target
SGLT
Related Pathways
Membrane Transporter/Ion Channel
Field of Research
Metabolic Disease
Smiles
[H][C@](C1)(C2)[C@@]1([H])C[C@H]2OC3=CC=C(C=C3)CC4=CC([C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)=CC=C4Cl
Molecular Formula
C25H29ClO6
Molecular Weight
460.95
References & Citations
[1]Song L, et al. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor. Clin Pharmacokinet. 2023 Mar;62 (3) :505-518.|[2]Zhao H, et al. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. Eur J Pharm Sci. 2022 Dec 1;179:106298.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SGLT1; SGLT2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470276-500 1x 500 µL
TAG-72 / CA72.4 (B72.3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400181-100 1x 100 µL
CD59 (heavy chain of Protectin) (BRA-10G), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040043-500 1x 500 µL
P21 / WAF1 (WA-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details